IL2 and melanoma: The combination of IL2 and ipilimumab (CTLA-4 checkpoint inhibitor) for the treatment of patients with melanoma led to large side effects expected from single agent treatment, with an increase in the number of peripheral IFN-γ producing CD8+ T-cells in most patients, which indicated the effectiveness of IL2 and ipilimumab combination to stimulate the immune response (Ray et al., 2016; Weide et al., 2017; Silk et al., 2019).